TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded) Meeting Abstract
| Authors: | Tung, N. M.; Robson, M. E.; Ventz, S.; Santa-Maria, C. A.; Marcom, P. K.; Nanda, R.; Shah, P. D.; Ballinger, T. J.; Yang, E. S. H.; Melisko, M. E.; Brufsky, A.; Vinayak, S.; Demeo, M.; Jenkins, C.; Domchek, S. M.; Wulf, G. M.; Krop, I. E.; Wolff, A. C.; Winer, E. P.; Garber, J. E.; Translational Breast Cancer Research Consortium |
| Abstract Title: | TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368300125 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.1002 |
| Notes: | Meeting Abstract: 1002 -- Source: Wos |
